8 October 2024
Rapid emergency vaccine development in months
- Verovaccines develops the first recombinant subunit vaccine against the current bluetongue virus -3 (BTV-3) outbreak that impacts sheep and cattle in Europe
- Using a new vaccine construction technology, first vaccines were generated within weeks. Within 9 months, 90% of the dossier was completed
- The company uses its new capabilities for fast emergency responses and cost-efficient classical vaccine development in animal health